Description

Salazopyrin-EN-TABS (sulfasalazine) Coated Tablets 500 mg. №100

Ingredients

Active ingredient: Each tablet contains 500 mg of sulfasalazine. Other inactive ingredients include cellulose, magnesium stearate, and colloidal silicon dioxide.

Dosage

Dosage: The usual adult dose is 2 to 3 tablets daily, taken in divided doses. The dosage may vary depending on the condition being treated. Consult a healthcare provider for personalized dosing instructions.

Indications

Indications: Salazopyrin-EN-TABS are indicated for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. It works by reducing inflammation in the colon.

Contraindications

Contraindications: Do not use Salazopyrin-EN-TABS if you are allergic to sulfasalazine or any of the inactive ingredients. It is contraindicated in patients with intestinal or urinary obstruction.

Directions

Directions: Swallow the tablets whole with a full glass of water. Do not crush or chew the tablets. Take as directed by your healthcare provider.

Scientific Evidence

Salazopyrin-EN-TABS have been extensively studied for their efficacy in treating inflammatory bowel diseases. Research published in the Journal of Gastroenterology and Hepatology demonstrated the effectiveness of sulfasalazine in inducing and maintaining remission in patients with ulcerative colitis.

Additional Information

It is important to monitor for potential side effects such as nausea, headache, and rash while taking Salazopyrin-EN-TABS. Regular blood tests may be required to check for any adverse effects on the liver or blood cells.

Pharmacological Effects: Sulfasalazine works by reducing inflammation in the colon through its active metabolites. It inhibits the production of inflammatory chemicals, thereby alleviating symptoms associated with inflammatory bowel diseases.

Clinical Trials: A randomized controlled trial published in the American Journal of Gastroenterology compared the efficacy of sulfasalazine with other conventional treatments for Crohn’s disease. The study concluded that sulfasalazine was effective in reducing disease activity and improving quality of life in patients.